Eli Lilly and Company
NYSE:LLY · New York Stock Exchange
-$10.54 today
Vol 2.77M · Avg 3.19M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $20.6B +94.9% | $10.6B +102.1% | $5.2B -16.1% | $6.2B +11.9% | $5.6B | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $2.0B +13.0% | $1.8B +15.7% | $1.5B +0.3% | $1.5B -1.6% | $1.5B | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$1.7B +36.4% | -$2.7B -14.6% | -$2.3B -7.1% | -$2.2B -172.4% | -$802.3M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $626.0M -3.0% | $645.6M +2.7% | $628.5M +69.4% | $371.1M +8.3% | $342.8M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$8.1B -50.3% | -$5.4B -76.3% | -$3.1B -381775.0% | -$800.0K +99.9% | -$1.0B | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$7.0B -224.8% | -$2.2B +12.1% | -$2.5B -718.1% | -$299.6M +76.6% | -$1.3B | $592.6M | $1.3B | $626.2M |
| Inventory | -$4.7B -86.3% | -$2.5B -76.0% | -$1.4B -137.6% | -$599.7M -154.2% | -$235.9M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $10.2B +290.5% | $2.6B -39.0% | $4.3B +221.0% | $1.3B +231.4% | -$1.0B | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$6.6B -98.4% | -$3.3B +3.5% | -$3.5B -697.2% | -$433.2M -128.6% | $1.5B | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $3.4B -13.7% | $3.9B +73.4% | $2.2B +37.1% | $1.6B -4.4% | $1.7B | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $16.8B +90.7% | $8.8B +108.0% | $4.2B -44.1% | $7.6B +3.0% | $7.4B | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$7.8B +6.7% | -$8.4B -13.7% | -$7.4B -147.6% | -$3.0B -50.9% | -$2.0B | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$661.0M +30.3% | -$947.7M +9.3% | -$1.0B -219.2% | -$327.2M +56.2% | -$747.4M | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$645.0M +16.9% | -$775.8M +6.4% | -$829.0M -17.2% | -$707.6M +30.2% | -$1.0B | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $964.0M +84.5% | $522.5M -25.4% | $700.3M +51.1% | $463.6M -45.3% | $847.4M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$2.8B +8.3% | -$3.0B -20.2% | -$2.5B -89.3% | -$1.3B -107.6% | -$644.3M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$11.0B -18.0% | -$9.3B -30.0% | -$7.2B -90.1% | -$3.8B -31.2% | -$2.9B | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $8.1B -9.6% | $8.9B +2.9% | $8.6B +14051.5% | -$62.0M -112.4% | $501.4M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $0 | $0 | $0 | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$4.1B -64.3% | -$2.5B -233.3% | -$750.0M +50.0% | -$1.5B -20.0% | -$1.3B | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | -$5.4B -15.0% | -$4.7B -15.0% | -$4.1B -15.1% | -$3.5B -14.5% | -$3.1B | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$772.0M -57.4% | -$490.6M -46.4% | -$335.0M -8.4% | -$308.9M -4.4% | -$295.9M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$2.2B -279.9% | $1.2B -64.8% | $3.5B +164.7% | -$5.4B -30.9% | -$4.1B | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $372.0M +225.4% | -$296.7M -276.0% | $168.6M +200.6% | -$167.6M +18.5% | -$205.7M | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $4.0B +789.3% | $449.8M -40.2% | $751.6M +142.9% | -$1.8B -1185.2% | $161.4M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $9.0B +2065.6% | $414.3M +113.1% | -$3.2B -168.5% | $4.6B -14.6% | $5.4B | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Johnson & Johnson
NYSE:JNJ
$552.89B
AbbVie Inc.
NYSE:ABBV
$382.93B
Merck & Co., Inc.
NYSE:MRK
$282.33B
Novartis AG
NYSE:NVS
$281.96B
AstraZeneca PLC
NYSE:AZN
$271.39B
Novo Nordisk A/S
NYSE:NVO
$191.48B
Amgen Inc.
NASDAQ:AMGN
$180.94B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.75B
Pfizer Inc.
NYSE:PFE
$144.02B
Sanofi
NASDAQ:SNY
$101.57B
SEC Filings
Recent regulatory filings
No filings found.
Does LLY generate free cash flow?
Eli Lilly and Company (LLY) generated $8.97B of free cash flow in fiscal 2025.
How much operating cash flow does LLY produce?
Operating cash flow was $16.81B, before capital expenditures of $7.84B.
Explore More
Continue the stock analysis
Jump to another research area for this company.